Managing Ocular Pain and Inflammation After Cataract Surgery - Part 1
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Details
Overview
This continuing medical education (CME) activity captures content from a live symposium held in October of 2016 in Chicago, Illinois. This certified CME activity is designed for ophthalmologists involved in the comanagement of postoperative cataract patients.A CME activity provided by Evolve Medical Education LLC and distributed with Advanced Ocular Care and Cataract & Refractive Surgery Today. Supported through an educational grant by Sun Pharmaceutical Industries Ltd. Learning Objectives
Upon completion of this activity, the participant should be able to: - Describe the pharmacokinetic properties of the bromfenac molecule
- Assess the ability of topical ophthalmic NSAIDs to treat postoperative inflammation and pain in a cataract patient
- Analyze the safety profile of the bromfenac molecule
- Discuss the obstacles patients face in compliance and adherence
- Develop a plan to communicate compliance obstacles with patients
Participation Method
To obtain AMA PRA Category 1 Credit™ for this activity, you must read the activity in its entirety and complete the Post Test/ Activity Evaluation Form, which consists of a series of multiple choice questions. To answer these questions online and receive real-time results, please visit evolvemeded.com and click “Online Courses.” Upon completing the activity and achieving a passing score of over 70% on the self-assessment test, you may print out a CME credit letter awarding 1 AMA PRA Category 1 Credit™. Alternatively, please complete the Post Test/Activity Evaluation Form and mail or fax to Evolve Medical Education LLC; PO Box 358; Pine Brook, NJ 07058; Fax: (610) 771-4443. The estimated time to complete this activity is 1 hour. Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty members have the following financial relationships with commercial interests: John Sheppard, MD, MMSc, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: 1-800-Doctors; AbbieVie; Alcon; Aldeyra; Allergan; ArcScan; Bausch + Lomb; Bio-Tissue; Clearside; Clearview; Eleven/Lexitas; EyeGate Research; Hovione; Imprimis Pharma; Inspire/Merck Pharmaceuticals; Isis Pharmaceuticals; Kala Pharmaceuticals; Lacrisciences; Lenstatin; LayerBio; Lumenis; Lux Biosciences; NiCox; NovaBay; Novartis/CibaVision; OcuCure; Oculeve; Ocular Therapeutics; Omeros; Pentavision; Pfizer; Portage; Rapid Pathogen Screening; Santen Pharmaceuticals; Science Based Health; Shire/SarCode Biosciences; Sjo/Nicox; Stemnion; Sun Pharmaceuticals; Synedegen; Talia Technology; TearLab; TearScience; Topivert; and Vistakon. Contracted Research: Alcon; Aldeyra; Allergan; ArcScan; Bausch + Lomb; Clearview; EyeGate Research; EyeRx Research; InSite Vision; Inspire/Merck Pharmaceuticals; Isis Pharmaceuticals; Kala Pharmaceuticals; Lux Biosciences; Oculeve; Ocular Therapeutics; Pfizer; Rapid Pathogen Screening; Rutech; Santen Pharmaceuticals; Senju; Shire/SarCode Biosciences; TearScience; Vistakon; and Xoma/Servier. Stock/Shareholder: 1-800-Doctors; Alphaeon; BioLayer; Clearside; EyeGate Research; EyeRx Research; Lacrisciences; Lumenis; NovaBay; Occuhub; OcuCare; Rapid Pathogen Screening; Shire/SarCode Biosciences; Stemnion; Strathspey Crowne; and TearLab. Johnny Gayton, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Abbott Medical Optics; Bausch + Lomb; Omerus; ScienceBased Health; Shire; and Sun Pharmaceutical Industries Ltd. John Wittpenn, MD, has had no financial agreements or affiliations during the past year. EDITORIAL SUPPORT DISCLOSURES Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; and Michelle Dalton, medical writer, have no financial relationships with commercial interests. Rishi Singh, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech; and Regeneron Pharmaceuticals.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, Advanced Ocular Care, Cataract & Refractive Surgery Today, or Sun Pharmaceutical Industries Ltd. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
